# Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites

> **NCT04058613** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 304 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** ALB Protein, Human
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04058613
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-10
- **Primary completion:** 2020-08-08
- **Final completion:** 2021-08-08
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058613, "Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04058613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*